SFXN3 and acute myeloid leukemia: Furthermore, we confirmed that SFXN3 was primarily over-expressed in AML patients, especially non-M3 patients, and that high SFXN3 in non-M3 AML patients was found to be associated with poor outcomes and frequent blast cells.